Cargando…

Health state utilities for non small cell lung cancer

BACKGROUND: Existing reports of utility values for metastatic non-small cell lung cancer (NSCLC) vary quite widely and are not all suitable for use in submissions in the UK. The aim of this study was to elicit UK societal based utility values for different stages of NSCLC and different grade III-IV...

Descripción completa

Detalles Bibliográficos
Autores principales: Nafees, Beenish, Stafford, Megan, Gavriel, Sonia, Bhalla, Shkun, Watkins, Jessamy
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579282/
https://www.ncbi.nlm.nih.gov/pubmed/18939982
http://dx.doi.org/10.1186/1477-7525-6-84
_version_ 1782160562906464256
author Nafees, Beenish
Stafford, Megan
Gavriel, Sonia
Bhalla, Shkun
Watkins, Jessamy
author_facet Nafees, Beenish
Stafford, Megan
Gavriel, Sonia
Bhalla, Shkun
Watkins, Jessamy
author_sort Nafees, Beenish
collection PubMed
description BACKGROUND: Existing reports of utility values for metastatic non-small cell lung cancer (NSCLC) vary quite widely and are not all suitable for use in submissions in the UK. The aim of this study was to elicit UK societal based utility values for different stages of NSCLC and different grade III-IV toxicities commonly associated with chemotherapy treatments. Toxicities included neutropenia, febrile neutropenia, fatigue, diarrhoea, nausea and vomiting, rash and hair loss. METHODS: Existing health state descriptions of metastatic breast cancer were revised to make them suitable as descriptions of metastatic NSCLC patients on second-line treatment. The existing health states were used in cognitive debrief interviews with oncologists (n = 5) and oncology specialist nurses (n = 5). Changes were made as suggested by the clinical experts. The resulting health states (n = 17) were piloted and used in a societal based valuation study (n = 100). Participants rated half of the total health states in a standard gamble interview to derive health state utility scores. Data were analysed using a mixed model analysis. RESULTS: Each health state described the symptom burden of disease and impact on different levels of functioning (physical, emotional, sexual, and social). The disutility related to each disease state and toxicity was estimated and were combined to give health state values. All disease states and toxicities were independent significant predictors of utility (p < 0.001). Stable disease with no toxicity (our base state) had a utility value of 0.653. Utility scores ranged from 0.673 (responding disease with no toxicity) to 0.473 for progressive disease. CONCLUSION: This study reflects the value that society place on the avoidance of disease progression and severe toxicities in NSCLC.
format Text
id pubmed-2579282
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-25792822008-11-05 Health state utilities for non small cell lung cancer Nafees, Beenish Stafford, Megan Gavriel, Sonia Bhalla, Shkun Watkins, Jessamy Health Qual Life Outcomes Research BACKGROUND: Existing reports of utility values for metastatic non-small cell lung cancer (NSCLC) vary quite widely and are not all suitable for use in submissions in the UK. The aim of this study was to elicit UK societal based utility values for different stages of NSCLC and different grade III-IV toxicities commonly associated with chemotherapy treatments. Toxicities included neutropenia, febrile neutropenia, fatigue, diarrhoea, nausea and vomiting, rash and hair loss. METHODS: Existing health state descriptions of metastatic breast cancer were revised to make them suitable as descriptions of metastatic NSCLC patients on second-line treatment. The existing health states were used in cognitive debrief interviews with oncologists (n = 5) and oncology specialist nurses (n = 5). Changes were made as suggested by the clinical experts. The resulting health states (n = 17) were piloted and used in a societal based valuation study (n = 100). Participants rated half of the total health states in a standard gamble interview to derive health state utility scores. Data were analysed using a mixed model analysis. RESULTS: Each health state described the symptom burden of disease and impact on different levels of functioning (physical, emotional, sexual, and social). The disutility related to each disease state and toxicity was estimated and were combined to give health state values. All disease states and toxicities were independent significant predictors of utility (p < 0.001). Stable disease with no toxicity (our base state) had a utility value of 0.653. Utility scores ranged from 0.673 (responding disease with no toxicity) to 0.473 for progressive disease. CONCLUSION: This study reflects the value that society place on the avoidance of disease progression and severe toxicities in NSCLC. BioMed Central 2008-10-21 /pmc/articles/PMC2579282/ /pubmed/18939982 http://dx.doi.org/10.1186/1477-7525-6-84 Text en Copyright © 2008 Nafees et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Nafees, Beenish
Stafford, Megan
Gavriel, Sonia
Bhalla, Shkun
Watkins, Jessamy
Health state utilities for non small cell lung cancer
title Health state utilities for non small cell lung cancer
title_full Health state utilities for non small cell lung cancer
title_fullStr Health state utilities for non small cell lung cancer
title_full_unstemmed Health state utilities for non small cell lung cancer
title_short Health state utilities for non small cell lung cancer
title_sort health state utilities for non small cell lung cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579282/
https://www.ncbi.nlm.nih.gov/pubmed/18939982
http://dx.doi.org/10.1186/1477-7525-6-84
work_keys_str_mv AT nafeesbeenish healthstateutilitiesfornonsmallcelllungcancer
AT staffordmegan healthstateutilitiesfornonsmallcelllungcancer
AT gavrielsonia healthstateutilitiesfornonsmallcelllungcancer
AT bhallashkun healthstateutilitiesfornonsmallcelllungcancer
AT watkinsjessamy healthstateutilitiesfornonsmallcelllungcancer